Cover Image

PD-1 blockade boost vaccine-induced anti-HIV responses in the absence of HIV reactivation

Saved in:

Bibliographic Details
Main Authors:	J.G. Prado (Author), M. Marin Lopez (Author), E. Jimenez-Moyano (Author), D. Ouchi (Author), O. Blanch-Lombarte (Author), D. Gorman (Author), T. Hanke (Author), C. Brander (Author), B. Howell (Author), B. Mothe (Author)
Format:	Book
Published:	Elsevier, 2019-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

20 Rapid CTL recognition of HIV-1 latently infected cells depends on the levels of inducible viral reactivation and CTL activation status
by: A. Ruiz, et al.
Published: (2017)

OA3-2 PD-1 blockade in 12 HIV-infected patients with lung cancer
by: A. Samri, et al.
Published: (2017)

Enhancement of antiviral CD8 T-cell responses and complete remission of metastatic melanoma in an HIV-1 infected subject treated with pembrolizumab
by: O. Blanch-Lombarte, et al.
Published: (2019)

OP 1.10 - 00210 Clonal Dynamics within HIV-Infected CD4 T Cell Reservoirs after PD-1 Blockade under ART
by: L. Perez, et al.
Published: (2022)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
by: Laura Jimbu, et al.
Published: (2021)

Blockade of dengue virus entry into myeloid cells by endocytic inhibitors in the presence or absence of antibodies.
by: Ana C Carro, et al.
Published: (2018)

Cellular modulation and HIV reactivation in response to serial treatment of latently HIV infected CD4 T cells with histone deacetylase inhibitors (HDACi)
by: J. Maxwell, et al.
Published: (2019)

HIV conserved region vaccine in early cART-treated subjects (BCN01): impact on immunogenicity and the latent reservoir
by: S. Morón-López, et al.
Published: (2015)

The steroid receptor coactivators are targets for reactivation of HIV latency
by: B.C. Nikolai, et al.
Published: (2015)

CD8+ sensing relies on nanomolar levels of antigen presented upon HIV-1 reactivation
by: A. Ruiz, et al.
Published: (2015)

OP 8.3 - 00028 HIV-vaccine induced, broad and polyfunctional CD4 and CD8 T cell responses are associated with prolonged time off ART and lower pVL at the end of ATI in the AELIX-002 therapeutic vaccine trial
by: B. Mothe, et al.
Published: (2022)

Novel prime-boost vaccine strategies against HIV-1
by: Jean-Louis Excler, et al.
Published: (2019)

Blockade of PD-L1/PD-1 signaling promotes osteo-/odontogenic differentiation through Ras activation
by: So Mi Jeon, et al.
Published: (2022)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
by: Jin-Yu Sun, et al.
Published: (2020)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
by: Mengjie Wang, et al.
Published: (2022)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
by: Luisa Chocarro de Erauso, et al.
Published: (2020)

OP 8.5 - 00104 TGF-beta Blockade to Stop HIV White Noise: a New "Release and Kill" HIV Strategy
by: E. Martinelli, et al.
Published: (2022)

21 T regulatory cell depletion in controller macaques reactivates SIV and boosts CTLs
by: T. He, et al.
Published: (2016)

Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer
by: Ge Y, et al.
Published: (2022)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
by: Jiqiao Yang, et al.
Published: (2019)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
by: Shiyun Chen, et al.
Published: (2023)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
by: Dan Zheng, et al.
Published: (2022)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
by: Man Wang, et al.
Published: (2023)

27 HIV-associated gastrointestinal microbial dysbiosis influences the efficacy of anti-HIV immunity by immune checkpoint blockade
by: I.N. SahBandar, et al.
Published: (2017)

Sezary syndrome revealed by PD‐L1 blockade for tumor stage mycosis fungoides
by: Jérémie Delaleu, et al.
Published: (2024)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
by: Mingxia Zhao, et al.
Published: (2019)

B cell depletion alone or in combination with IL-15 or PD-1 blockade facilitates enhanced control of virus replication in SIV-infected rhesus macaques
by: L.J. Picker, et al.
Published: (2019)

Effects of heme degradation products on reactivation of latent HIV-1
by: Z. Melkova, et al.
Published: (2015)

A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model
by: Yuhua Wei, et al.
Published: (2022)

Pharmacological Inhibition of PPAR<sub>y</sub> Boosts HIV Reactivation and Th17 Effector Functions, while Preventing Progeny Virion Release and <i>de novo</i> Infection
by: Delphine Planas, et al.
Published: (2020)

Window of opportunity with PD1 blockade before chemoradiotherapy for an advanced stage clear cell carcinoma of the cervix
by: Marie-Gabrielle Courtès, et al.
Published: (2024)

HIV treatment will boost prevention and strengthen health systems, says The world health report 2004
Published: (2004)

Ingenol derivatives are potent reactivators of latent HIV
by: V. Planelles, et al.
Published: (2015)

4 New HIV specific latency reversing agents with novel targets that synergise with HIV Tat and the bromodomain inhibitor, JQ1 to reactivate HIV from primary cells.
by: J. Jacobson, et al.
Published: (2017)

Biomimetic "Gemini nanoimmunoregulators" orchestrated for boosted photoimmunotherapy by spatiotemporally modulating PD-L1 and tumor-associated macrophages
by: Honglin Huang, et al.
Published: (2024)

The Blockade Runners
by: Verne, Jules, 1828-1905; D'Anvers, N., -1933 [Translator]

Latent HIV dynamics and implications for sustained viral suppression in the absence of antiretroviral therapy
by: John M. Murray
Published: (2018)

Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy
by: Youngjoo Lee, et al.
Published: (2024)

Sequential delivery of PD-1/PD-L1 blockade peptide and IDO inhibitor for immunosuppressive microenvironment remodeling via an MMP-2 responsive dual-targeting liposome
by: Chuan Hu, et al.
Published: (2023)

Galectin-1 promotes HIV-1 latency reactivation
by: J. Rubione, et al.
Published: (2019)